Kiniksa Pharmaceuticals International, plc (KNSA)

KNSA Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	677.56	423.24	270.26	220.18	38.54
Revenue Growth (YoY)	60.09%	56.61%	22.75%	471.24%	-
Cost of Revenue	77.67	60.91	33.41	22.9	9.1
Gross Profit	599.89	362.33	236.85	197.29	29.44
Selling, General & Admin	196.27	168.01	129.43	97.95	85.95
Research & Development	96.85	111.62	76.1	65.49	99.3
Other Operating Expenses	229.55	128.31	56.52	24.07	0.84
Total Operating Expenses	522.67	407.95	262.05	187.51	186.08
Operating Income	77.22	-45.62	-25.2	9.77	-156.64
Total Non-Operating Income (Expense)	11.65	9.46	8.54	1.25	0.1
Pretax Income	88.87	-36.15	-16.65	11.03	-156.54
Provision for Income Taxes	-29.86	-7.04	30.74	172.34	-1.39
Net Income	59.01	-43.19	14.08	183.36	-157.92
Net Income to Common	59.01	-43.19	14.08	183.36	-157.92
Net Income Growth	-	-	-92.32%	-	-
Shares Outstanding (Basic)	74	71	70	69	69
Shares Outstanding (Diluted)	79	71	72	70	69
Shares Change (YoY)	10.58%	-0.69%	2.13%	2.69%	10.89%
EPS (Basic)	0.80	-0.60	0.20	2.64	-2.30
EPS (Diluted)	0.75	-0.60	0.20	2.60	-2.30
EPS Growth	-	-	-92.31%	-	-
Free Cash Flow	136.42	25.41	13.17	5.7	-126.71
Free Cash Flow Growth	436.82%	92.94%	130.99%	-	-
Free Cash Flow Per Share	1.73	0.36	0.18	0.08	-1.85
Gross Margin	88.54%	85.61%	87.64%	89.60%	76.39%
Operating Margin	11.40%	-10.78%	-9.32%	4.44%	-406.38%
Profit Margin	8.71%	-10.21%	5.21%	83.28%	-409.72%
FCF Margin	20.13%	6.00%	4.87%	2.59%	-328.75%
EBITDA	78.78	-43.92	-22.86	12.18	-154.28
EBITDA Margin	11.63%	-10.38%	-8.46%	5.53%	-400.27%
EBIT	77.22	-45.62	-25.2	9.77	-156.64
EBIT Margin	11.40%	-10.78%	-9.32%	4.44%	-406.38%
Effective Tax Rate	-33.60%	19.48%	-184.58%	1563.01%	0.88%

Updated Feb 24, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q